ReviewCurrent hypertension reports2000
Endothelial dysfunction and atherosclerosis: endothelin receptor antagonists as novel therapeutics.
Review in Current hypertension reports, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 57 citations in OpenAlex.
- AqueousJournal of diabetes and metabolic disorders · 2020Article
- In vitro affinity maturation of antibody against membrane-bound GPCR molecules.Applied microbiology and biotechnology · 2019Article
- Comparison of Serum Levels of Endothelin-1 in Chronic Periodontitis Patients Before and After Treatment.Journal of clinical and diagnostic research : JCDR · 2017Article
- Serum Concentrations of Endothelin-1 and Matrix Metalloproteinases-2, -9 in Pre-Hypertensive and Hypertensive Patients with Type 2 Diabetes.International journal of molecular sciences · 2016Article
- The Protective Effect of Antioxidants Consumption on Diabetes and Vascular Complications.Diseases (Basel, Switzerland) · 2016Review
- Air Pollution-Induced Vascular Dysfunction: Potential Role of Endothelin-1 (ET-1) System.Cardiovascular toxicology · 2016Review
- Orphan nuclear receptor Nur77 is a novel negative regulator of endothelin-1 expression in vascular endothelial cells.Journal of molecular and cellular cardiology · 2014Article
- Association of promoter region single nucleotide polymorphisms at positions -819C/T and -592C/A of interleukin 10 gene with ischemic heart disease.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2012Article
- Article
- Endothelin.Cellular and molecular life sciences : CMLS · 2011Review
- Endothelial nitric oxide synthase transgenic models of endothelial dysfunction.Pflugers Archiv : European journal of physiology · 2010Review
- eNOS, metabolic syndrome and cardiovascular disease.Trends in endocrinology and metabolism: TEM · 2009Review
- The therapeutic potential of endothelin receptor antagonists in cardiovascular disease.Current hypertension reports · 2001Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atherosclerosis, a chronic systemic disease of the vasculature with an inflammatory component, is the primary cause of cardiovascular morbidity and mortality in industrialized countries. It is associated with the impairment of endothelium-dependent relaxation in the coronary, systemic circulation due to decreased bioavailability of nitric oxide, and increased release oxygen-derived free radicals, thus promoting vasoconstriction, leukocyte adhesion, thrombosis, inflammation, and cell proliferation. Expression of endothelin (ET)-1, a 21-amino acid peptide and major isoform of the endothelin peptide family, is produced by endothelial, vascular smooth muscle cells, and macrophages and acts through Gi-protein-coupled ET(A) and ET(B) receptors. Endothelin-1 increases in hypercholesterolemia and atherosclerosis in humans and experimental animals. This paper reviews current experimental and clinical evidence for the involvement of ET-1 in atherogenesis. Furthermore, the effects of ET receptor blockade on experimental hypercholesterolemia and atherosclerosis will be discussed. As chronic endothelin blockade inhibits fatty streak formation and improves vascular function in experimental hypercholesterolemia, hypertension, and heart failure, and as it restores nitric oxide (NO)-mediated endothelial function and reduces atheroma formation in animals with atherosclerosis, endothelin receptor blockade may therefore offer a novel approach for the treatment of atherosclerosis and its vascular complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.